Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379612 | 1.00 | TRPA1 (0.33) | TRPA1 | |
| Fluoride SCHEMBL28557472 | 0.98 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL27595489 | 0.82 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL29394860 | 0.77 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL30218263 | 0.77 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL23446692 | 0.75 | NQO2 (0.31) | — | |
| SCHEMBL2186641 | 0.74 | KDM4E (0.33) | TRPA1 | |
| SCHEMBL2186647 | 0.74 | KDM4E (0.33) | TRPA1 | |
| SCHEMBL9523683 | 0.74 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL9523696 | 0.74 | TRPA1 (0.36) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | TOBIRA THERAPEUTICS INC (US) | 2020-09-24 | — | — | US | claimed |
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. | 2017-04-20 | — | — | US | claimed |
| EP-3148538-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | Tobira Therapeutics, Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| WO-2016123541-A2 | CENICRIVIROC FOR THE TREATMENT OF ENCEPHALITIS INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | claimed |
| WO-2015187663-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | TOBIRA THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| US-8362058-B2 | Bicyclic compound, production and use thereof | TOBIRA THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-8183273-B2 | 8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-N-[4-[[N-methyl-N-(tetrahydropyran-4-yl)amino]methyl]phenyl]-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide; HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disease | TOBIRA THERAPEUTICS, INC. (US) | 2012-05-22 | — | — | US | claimed |
| EP-1144369-B1 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-21 | — | — | EP | claimed |
| US-6762178-B2 | FOR USE IN TREATMENT OF DISEASE CONDITIONS MEDIATED BY TNF-ALPHA, SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE, DEGENERATIVE CARTILAGE LOSS | WYETH HOLDINGS CORPORATION | 2004-07-13 | — | — | US | claimed |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | AMERICAN CYANAMID COMPANY (US) | 2001-12-27 | — | — | US | claimed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-4166174-A | ANALGESICS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1979-08-28 | — | — | US | claimed |
| JP-53009322-A | — | — | None | — | — | JP | disclosed |
| JP-59013760-A | — | — | None | — | — | JP | disclosed |
| JP-56083477-A | — | — | None | — | — | JP | disclosed |
| US-3951984-A | 3-Benzazocine compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-04-20 | — | — | US | disclosed |
| US-3936462-A | CNS DEPRESSANT, ANALGESIC | STERLING DRUG INC. (US) | 1976-02-03 | — | — | US | disclosed |
| US-3932422-A | ANALGESICS, NARCOTIC ANTAGONISTS | STERLING DRUG INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105969-A1 | CENICRIVIROC FOR THE TREATMENT OF HIV-2 INFECTION | CCR5, CCR2, CCR1 | TRPA1 2347/4885 |
| US-20200297700-A1 | BICYCLIC COMPOUND, PRODUCTION AND USE THEREOF | CCR5, CCR1, CCR2 | TRPA1 68/4885 |
| US-20010056088-A1 | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors | PTDSS1, SAT1, TNF | TRPA1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.